On May 2, 2019 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, reported that William Grossman, M.D., Ph.D. has joined the Company as Chief Medical Officer (Press release, Arcus Biosciences, MAY 2, 2019, View Source [SID1234535583]). Dr. Grossman will oversee all aspects of the Company’s global clinical development strategy and operations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to have Dr. Grossman join Arcus during this seminal period in the advancement and expansion of our clinical development programs," said Terry Rosen, Ph.D., Chief Executive Officer of Arcus. "Dr. Grossman has a distinguished background as a practicing oncologist and has successfully led multiple global cancer immunotherapy trials, from early-stage to commercialization. He will complement the outstanding team that has already been assembled and advanced Arcus’s first four product candidates into clinical development. I look forward to having Bill as a colleague and critical member of our senior leadership team as we move towards later stage clinical trials."

"I am honored to join Arcus at this pivotal time, with multiple Phase 1 readouts in 2019," commented Dr. Grossman. "Arcus’s thoughtful strategy in leveraging promising biological targets, potentially best-in-class molecules, comprehensive and unique approach to clinical development and experienced team were key reasons for joining the Company. I look forward to contributing to the shared commitment of developing innovative cancer immunotherapies for patients."

Dr. Grossman has extensive experience leading successful global clinical organizations, including direct medical accountability for more than 50 clinical trials spanning Phase 1 through Phase 3. Dr. Grossman joins Arcus from Bellicum Pharmaceuticals, where he served as Chief Medical Officer and was responsible for the company’s clinical development, regulatory affairs, clinical operations, and medical affairs organizations. Prior to Bellicum, Dr. Grossman was the Global Group Medical Director for Cancer Immunotherapy at Genentech, where he led the clinical development of TECENTRIQ in gastrointestinal cancers and of cancer immunotherapy combinations across all solid tumor types. Dr. Grossman designed and led the Phase 1b/2 MORPHEUS platform, a rapid and efficient paradigm for the evaluation of cancer immunotherapy combinations. Before joining Genentech, Dr. Grossman led the development and execution of the U.S. & Global medical affairs strategy for the oncology franchise at AbbVie. Previously, he served as Senior Vice President, Research & Clinical Development at Biothera, where he oversaw all discovery and clinical development efforts in oncology and immunology. In addition, Dr. Grossman has held leadership positions in research, clinical development, and medical affairs at Baxter Healthcare and Merck & Co., where he was involved in the clinical evaluation of anti-cancer vaccines, immunomodulatory agents, small molecules and biologics for oncology.

Prior to joining the industry, Dr. Grossman held various positions with the Children’s Hospital of Wisconsin/Medical College of Wisconsin where he was Founder and Medical Director of the Clinical Immunodiagnostic and Research Laboratory, Professor for Microbiology and Genetics, and Director of the Hematology/Oncology/Bone Marrow Transplant Division for the Immunodeficiency Transplant Program. Dr. Grossman earned his M.D. and Ph.D. (Immunology) degrees from Washington University School of Medicine’s Medical Scientist Training Program and completed his medical training in the Division of Pediatric Biology/Medicine at the Washington University School of Medicine.